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ABSTRACT
Introduction Avelumab, an antiprogrammed death
ligand-1 antibody, is approved as a monotherapy for
treatment of metastatic Merkel cell carcinoma and
advanced urothelial carcinoma, and in combination with
axitinib for advanced renal cell carcinoma. We report the
efficacy and safety of first-line avelumab in advanced non-
small cell lung cancer (NSCLC).
Methods In a phase I expansion cohort of the JAVELIN
Solid Tumor trial, patients with treatment-naive, metastatic,
or recurrent NSCLC received 10 mg/kg avelumab
intravenously every 2 weeks. Endpoints included best
overall response, duration of response (DOR), progression-
free survival (PFS), overall survival (OS), and safety.
Results Overall, 156 patients were enrolled and treated.
Median duration of follow-up was 18.6 months (range, 15
to 23 months). The objective response rate was 19.9%
(95% CI, 13.9 to 27.0), including complete response in
3 (1.9%) and partial response in 28 (17.9%). Median
DOR was 12.0 months (95% CI, 6.9 to not estimable).
Median PFS was 4.0 months (95% CI, 2.7 to 5.4) and
the 6-month PFS rate was 38.5% (95% CI, 30.7 to 46.3).
Median OS was 14.1 months (95% CI, 11.3 to 16.9) and
the 12-month OS rate was 56.6% (95% CI, 48.2 to 64.1).
Treatment-related adverse events (TRAEs) occurred in 107
patients (68.6%), including grade ≥3 TRAEs in 19 (12.2%).
Immune-related adverse events and infusion-related
reactions occurred in 31 (19.9%) and 40 patients (25.6%),
respectively. No treatment-related deaths occurred.
Conclusion Avelumab showed antitumor activity with
a tolerable safety profile as a first-line treatment in
patients with advanced NSCLC. These data support further
investigation of avelumab in the phase III JAVELIN Lung
100 study.
Trial registration details ClinicalTrials.gov
NCT01772004; registered January 21, 2013.

INTRODUCTION
Monoclonal antibodies targeting immune
checkpoint proteins are established treatments for metastatic non-
small cell lung

cancer (NSCLC). In 2016, the antiprogrammed cell death protein-1 (PD-1) antibody pembrolizumab was approved as
first-line monotherapy for patients with metastatic NSCLC without targetable epidermal
growth factor receptor (EGFR) or anaplastic
lymphoma kinase (ALK) gene defects and
with ≥50% programmed death ligand 1 (PD-
L1) expression on tumor cells.1 2 Based on
results of the phase III KEYNOTE-042 study,
approval of pembrolizumab monotherapy in
the first-line setting was expanded in the USA
for patients with ≥1% PD-L1 expression on
tumor cells.3 By contrast, in a phase III trial
of first-
line nivolumab (anti-
PD-1) monotherapy versus platinum-based chemotherapy
in patients with advanced NSCLC with ≥5%
PD-L1 expression on tumor cells, nivolumab
did not significantly improve progression-
free survival (PFS) or overall survival (OS).4
More recently, immune checkpoint inhibitors
(pembrolizumab and atezolizumab) have
been assessed in combination with chemotherapy in the first-line NSCLC setting and
have shown superior efficacy compared with
chemotherapy alone in several randomized
trials.5–7
Avelumab, a human anti-
PD-
L1 immunoglobulin G1 antibody with a wild-type Fc
region, has been shown in preclinical models
to induce antitumor activity via adaptive
and innate effector cells.8 9 Avelumab has
been approved in some countries as monotherapy for metastatic Merkel cell carcinoma,
as monotherapy for advanced urothelial
carcinoma that has not progressed with
platinum-
containing chemotherapy (first-
line maintenance therapy) or following
disease progression, and in combination
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with axitinib for first-line treatment of advanced renal
cell carcinoma.10 11 In previous clinical trials, avelumab
has demonstrated clinical activity and a tolerable safety
profile in patients with various other tumor types,
including platinum-treated NSCLC.12–16 Here, we report
efficacy and safety data from a phase I expansion cohort
of the JAVELIN Solid Tumor trial in which patients with
advanced NSCLC received first-line avelumab. Preliminary findings from this cohort led to the initiation of the
phase III JAVELIN Lung 100 study (NCT02576574) of
first-line avelumab versus platinum-based doublet chemotherapy in patients with PD-L1-positive NSCLC.17

MATERIALS AND METHODS
Study design and treatment
JAVELIN Solid Tumor (NCT01772004) is an international, multicohort, open-label phase I trial. In this phase
Ib NSCLC expansion cohort, patients, who were unselected for PD-L1 expression, had histologically confirmed
stage IV (per International Association for the Study of
Lung Cancer classification, seventh edition)18 or recurrent
NSCLC, no prior treatment for metastatic or recurrent
disease, and no activating EGFR mutation or ALK translocation/rearrangement (tumors with non-squamous cell
histology were tested if mutational status was unknown).
General eligibility criteria for the JAVELIN Solid Tumor
trial have been reported previously.12
Procedures and assessments
Patients received avelumab 10 mg/kg by intravenous
infusion every 2 weeks until disease progression, unacceptable toxicity, or other criteria for withdrawal were
met. Patients were permitted to continue treatment
despite progression according to the investigator’s decision and in agreement with the patient if no new symptoms appeared, existing symptoms did not worsen,
Eastern Cooperative Oncology Group (ECOG) performance status did not decrease, and the investigator did
not consider it necessary to administer a salvage therapy.
Dose reductions were not permitted. Premedication with
an antihistamine (diphenhydramine or equivalent) and
acetaminophen was given 30 to 60 min before each infusion. Treatment was permanently discontinued for any
grade ≥3 adverse event (AE) except for specified transient AEs (reported previously).12 13 Grade 2 AEs were
managed by treatment delays of ≤2 subsequent omitted
doses; events that did not resolve to grade ≤1 or recurred
resulted in permanent discontinuation of avelumab. Clinical activity and safety were analyzed in all patients who
received ≥1 dose of avelumab.
Tumor assessments were performed every 6 weeks for
the first year and every 12 weeks thereafter by investigators according to Response Evaluation Criteria in Solid
Tumors 1.1 (RECIST 1.1) and modified immune-related
response criteria.19 Safety was assessed every 2 weeks at each
visit, and AEs were graded according to National Cancer
Institute Common Terminology Criteria for Adverse
2

Events V.4.0. Immune-related AEs (irAEs) were identified
using a prespecified list of Medical Dictionary for Regulatory Activities (MedDRA)-preferred terms followed by
comprehensive medical review. Infusion-related reactions
(IRRs) were identified using an expanded definition that
included both a prespecified list of MedDRA-preferred
terms (IRR, drug hypersensitivity, or hypersensitivity reaction) that occurred post infusion within 48 hours, and
additional signs or symptoms that occurred on the day of
infusion and resolved within 2 days.
PD-
L1 expression was assessed using a proprietary
immunohistochemistry assay (PD-L1 IHC 73-10 pharmDx;
Dako, Carpinteria, California). In previous studies
comparing the 73-10 PD-L1 assay with the 22C3 assay used
in pembrolizumab trials, the 73-10 assay showed greater
sensitivity, and the ≥80% PD-L1 cut-off for the 73-10 assay
was found to be comparable to the ≥50% PD-L1 cut-off
for the 22C3 assay (manuscript in press).20 21 PD-L1-
positive status was predefined as PD-L1 expression of any
intensity on ≥1% of tumor cells; PD-L1 expression status
was also assessed using cut-offs of ≥50% and ≥80% in post
hoc analyzes.
Prespecified endpoints assessed in this expansion
cohort included confirmed best overall response, duration of response (DOR), and PFS based on investigator assessment according to RECIST 1.1, best overall
response based on investigator assessment according to
modified immune-related response criteria, OS, PD-L1
expression, and safety (all secondary endpoints in the
overall JAVELIN Solid Tumor trial protocol).
Statistical analysis
Planned enrollment was 150 patients, which was based
on the anticipated sample size required to estimate and
provide 95% Clopper-Pearson CIs for potential objective
response rates (ORRs). Safety data were summarized
using descriptive statistics. Time-to-event endpoints were
estimated using the Kaplan-
Meier method, while 95%
CIs for medians were calculated using the Brookmeyer-
Crowley method. P values for the association between
PD-L1 status and ORRs were determined using the Fisher’s exact test. Comparisons between other subgroups
were not prespecified and are reported descriptively.

RESULTS
Patient characteristics and disposition
Between March 18, 2015, and November 19, 2015, 156
patients were enrolled from seven countries in North
America, Europe, and Asia (table 1). The median age was
69.5 years (range, 41 to 90 years), 83 patients (53.2%)
were male, and most patients (108 (69.2%)) had an
ECOG performance status of 1. Tumor histology was
squamous in 46 patients (29.5%) and non-squamous in
110 (70.5%). A total of 139 patients (89.1%) were ever
smokers (current or previous) and 17 (10.9%) had never
smoked. PD-L1 expression was evaluable in 111 patients
(71.2%), of whom 88 (79.3%) had PD-L1-positive tumors
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Table 1 Patient demographics and baseline characteristics

Table 1 Continued

Characteristic

Characteristic

N=156

Age

N=156

PD-L1 expression ≥50% of tumor cells, n (%)

 Median (range), years

69.5 (41 to 90)

 Positive

53 (34.0)

 <65, n (%)

51 (32.7)

 Negative

58 (37.2)

 ≥65, n (%)

105 (67.3)

 Not evaluable§

45 (28.8)

Sex, n (%)

PD-L1 expression ≥80% of tumor cells, n (%)

 Male

83 (53.2)

 Positive

38 (24.4)

 Female

73 (46.8)

 Negative

73 (46.8)

 Not evaluable§

45 (28.8)

Geographic region, n (%)
 North America
 Europe
 Asia

127 (81.4)

*Both patients had an ECOG PS of 1 at baseline, which had increased
to 2 at the first dose of study treatment.
†Data missing for six patients.
‡This patient was permitted to enroll following discussions between
the investigator and the sponsor based on expected resistance to
available tyrosine kinase inhibitor therapy.
§Reasons for PD-L1 expression not being evaluable included tumor
sample containing insufficient tumor cells (<100), non-evaluable
sample type (eg, cytology specimen), and no tumor tissue available for
analysis.
ALK, anaplastic lymphoma kinase; ECOG PS, Eastern Cooperative
Oncology Group performance status; EGFR, epidermal growth factor
receptor; PD-L1, programmed death ligand-1.

25 (16.0)
4 (2.6)

Race, n (%)
 White
 Black or African American

124 (79.5)
12 (7.7)

 Asian

6 (3.8)

 Other

14 (9.0)

ECOG PS, n (%)
 0

46 (29.5)

 1

108 (69.2)

 2*

2 (1.3)

Smoking status, n (%)
 Never used

17 (10.9)

 Regular user

29 (18.6)

 Occasional user
 Former user

2 (1.3)
108 (69.2)

Time since first diagnosis, median (range),
months

2.0 (0.02 to 143.5)

Time since diagnosis of metastatic
disease, median (range), months†

1.5 (0.2 to 92.0)

Tumor histology, n (%)
 Squamous cell carcinoma
 Non-squamous cell carcinoma

46 (29.5)
110 (70.5)

EGFR mutation status, n (%)
 Wild type

137 (87.8)

 Mutant‡

1 (0.6)

 Unknown

18 (11.5)

ALK mutation status, n (%)
 Wild type
 Mutant
 Unknown

140 (89.7)
0
16 (10.3)

KRAS mutation status, n (%)
 Wild type
 Mutant
 Unknown

6 (3.8)
10 (6.4)
140 (89.7)

PD-L1 expression ≥1% of tumor cells, n (%)
 Positive

88 (56.4)

 Negative

23 (14.7)

 Not evaluable§

45 (28.8)

Continued

based on a ≥1% cut-off. EGFR and ALK mutation status
were unknown in 18 (11.5%) and 16 (10.3%), respectively.
At data cut-off (February 15, 2017), the median follow-up
was 18.6 months (range, 15 to 23 months). Patients
received a median of 12 avelumab infusions (range,
1 to 49) over a median duration of 5.5 months (range,
0.5 to 22.5 months). At data cut-off, 26 patients (16.7%)
remained on study treatment. Reasons for permanent
treatment discontinuation were disease progression (82
(52.6%)), AEs (24 (15.4%)), withdrawal of consent (9
(5.8%)), death (9 (5.8%)), and other reasons (6 (3.8%)).
Efficacy
Of 156 patients, 3 (1.9%) had a confirmed complete
response (CR) and 28 (17.9%) had a confirmed partial
response (PR), resulting in an ORR of 19.9% (95% CI,
13.9% to 27.0%); 17 patients (10.9%) were not evaluable for response per RECIST (missing evaluations or
not assessable; table 2). ORRs were observed in 17.4%
(95% CI, 7.8% to 31.4%) of patients with squamous and
20.9% (95% CI, 13.7% to 29.7%) of patients with non-
squamous histology. ORRs in ever smokers and never
smokers were 20.9% (95% CI, 14.4% to 28.6%) and
11.8% (95% CI, 1.5% to 36.4%), respectively. In patients
who had unknown EGFR or ALK mutation status, ORRs
were 16.7% (95% CI, 3.6% to 41.4%) and 18.8% (95%
CI, 4.0% to 45.6%), respectively. Of the three patients
who had a CR, two had a preceding PR. Response was
ongoing in 15 of 31 patients at data cut-off (figure 1A).
The median time to response was 11.4 weeks (range,
5.1 to 29.6 weeks) and the median DOR in patients with
confirmed responses was 12.0 months (95% CI, 6.93
months to not estimable). Of 142 patients who were
evaluable for changes in target lesions (ie, those with
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Table 2 Best overall response (per RECIST 1.1, based on
investigator assessment)
Response
Best overall response, n (%)
 Complete response

N=156
3 (1.9)

 Partial response

28 (17.9)

 Stable disease

68 (43.6)

 Progressive disease

40 (25.6)

 Not evaluable*

17 (10.9)

ORR (95% CI), %
Disease control rate, n (%)

19.9 (13.9 to 27.0)
99 (63.4)

*Includes patients with no post-baseline assessment (n=9);
stable disease of insufficient duration (<6 weeks without further
assessment available; n=4); new therapy started before first post-
baseline assessment (n=2); non-evaluable assessments (n=1); or
non-evaluable with progressive disease occurring >12 weeks after
study assessment (n=1).
ORR, objective response rate; RECIST, Response Evaluation
Criteria in Solid Tumors.

a baseline and on-
study tumor assessment available),
93 (65.5%) had a reduction in tumor size of any level,
while 43 (30.3%; including 12 patients with unconfirmed
responses) had ≥30% reduction (figure 1B and online
additional file 1), with no notable trends based on tumor
histology or smoking status (online additional file 2).
The median PFS in all patients was 4.0 months (95% CI,
2.7 to 5.4 months) and the 6-month PFS rate was 38.5%
(95% CI, 30.7% to 46.3%) (online additional file 3).
The median OS was 14.1 months (95% CI, 11.3 to 16.9
months) and the 12-month OS rate was 56.6% (95% CI,
48.2% to 64.1%) (online additional file 3).
In analyzes of efficacy in subgroups with PD-L1 expression levels of ≥1%, ≥50%, and ≥80%, ORRs by RECIST 1.1
were 19.3% (95% CI, 11.7% to 29.1%), 22.6% (95% CI,
12.3% to 36.2%), and 26.3% (95% CI, 13.4% to 43.1%),
respectively (table 3). Patients who were not evaluable for
PD-L1 status had an ORR of 26.7% (95% CI, 14.6% to
41.9%). Best change in target lesions by PD-L1 status is
shown in online additional file 2. In PD-L1+ and PD-L1−
subgroups (≥1% and <1% cut-offs, respectively), median
PFS was 4.0 months (95% CI, 2.7 to 6.0 months) and 1.5
months (95% CI, 1.35 to 5.4 months), and median OS
was 14.1 months (95% CI, 11.2 to 18.2 months) and 11.3
months (95% CI, 1.6 to not estimable), respectively.
In analyzes of response by immune-
related criteria,
four additional patients, who did not achieve a response
according to RECIST 1.1, had an objective response,
resulting in an immune-related ORR of 22.4%, including
immune-related CRs in four patients (2.6%) and immune-
related PRs in 31 patients (19.9%). In PD-L1 subgroups
with expression levels of ≥1%, ≥50%, and ≥80%, immune-
related ORRs were 23.9% (95% CI, 15.4% to 34.1%),
28.3% (95% CI, 16.8% to 42.3%), and 34.2% (95% CI,
19.6% to 51.4%), respectively. In the overall population,
4

Figure 1 (A) Time to and duration of response in patients
with confirmed complete response or confirmed partial
response (n=31). The first per-protocol scan was performed
after 6 weeks for the first tumor assessment (week 7). Median
follow-up was 18.6 months (range, 15 to 23 months). (B) Best
change from baseline in target lesions in evaluable patients
(patients with a baseline and at least one post-baseline lesion
assessment; n=142). *Patient with 415% increase in tumor
diameter imputed with a cap of 100%.

median PFS based on immune-related criteria was 6.9
months (95% CI, 5.4 to 9.7 months).
Safety
AEs (irrespective of relationship to treatment)
In total, 156 patients (100%) had an AE of any grade.
AEs led to permanent treatment discontinuation in 31
patients (19.9%). Twenty patients (12.8%) died following
an AE that was unrelated to treatment; no deaths were
considered related to treatment. IRR, identified using
an expanded definition, was the most common AE and
occurred in 40 patients (25.6%), including grade ≥3 AEs
in five patients (3.2%). Most IRRs (34 of 40 patients)
occurred after the first infusion, and eight patients (5.1%)
permanently discontinued treatment because of an IRR.
Treatment-related AEs
Treatment-related AEs (TRAEs) of any grade occurred
in 107 patients (68.6%; table 4). Of 19 patients (12.2%)
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Table 3 ORR according to tumor PD-L1 status (cut-off indicates percentage of tumor cells expressing PD-L1)
PD-L1 positive

PD-L1 negative

P value

≥1% cut-off
 Patients, n

88

23

 ORR (95% CI), %

19.3 (11.7 to 29.1)

8.7 (1.1 to 28.0)

0.353

 Median PFS (95% CI), months

4.0 (2.7 to 6.0)

1.5 (1.4 to 5.4)

–

 Median OS (95% CI), months

14.1 (11.2 to 18.2)

11.3 (1.6 to NE)

–

 Patients, n

53

58

–

 ORR (95% CI), %

22.6 (12.3 to 36.2)

12.1 (5.0 to 23.3)

0.207

 Median PFS (95% CI), months

5.4 (2.8 to 9.6)

2.4 (1.4 to 2.8)

–

 Median OS (95% CI), months

14.2 (11.9 to NE)

13.6 (6.8 to 18.2)

–

 Patients, n

38

73

–

 ORR (95% CI), %

26.3 (13.4 to 43.1)

12.3 (5.8 to 22.1)

0.109

 Median PFS (95% CI), months
 Median OS (95% CI), months

5.4 (2.7 to 11.1)
14.2 (12.4 to 16.9)

2.7 (1.4 to 4.2)
14.0 (8.4 to 19.7)

–
–

–

≥50% cut-off

≥80% cut-off

NE, not estimable (not reached); ORR, objective response rate; OS, overall survival; PD-L1, programmed death ligand 1 ; PFS, progression-
free survival.

who had a grade ≥3 TRAE, three (1.9%) had a grade 4
TRAE (IRR, pneumonitis, and acute respiratory distress
syndrome, which each occurred in one patient (0.6%)).
The only grade 3 TRAEs that occurred in >1 patient
were IRR (5 (3.2%)) and fatigue (4 (2.6%)). Seventeen
patients (10.9%) had a TRAE that led to permanent treatment discontinuation (online additional file 4).
Serious TRAEs
Serious TRAEs occurred in 15 patients (9.6%), and the
most common (≥2 patients) were IRR (4 (2.6%)) and
pneumonitis (2 (1.3%)).
Immune-related adverse events
Thirty-
one patients (19.9%) had an irAE, of which
one patient (0.6%) had a grade ≥3 irAE (pneumonitis;
table 5). The most common category was endocrine
irAEs, which included 15 patients (9.6%) with either
hypothyroidism or hyperthyroidism, and one patient
(0.6%) with adrenal insufficiency. In addition, cutaneous
irAEs, including immune-
mediated rash or pruritus,
occurred in 12 patients (7.7%), pneumonitis occurred in
five patients (3.2%), and immune-mediated diarrhea or
colitis occurred in three patients (1.9%).
DISCUSSION
In this study, first-line avelumab monotherapy showed
clinical activity and an acceptable safety profile in
patients with treatment-
naive advanced NSCLC. The
ORR was 19.9% and the median DOR was 12.0 months.
In comparison, ORRs in studies of avelumab in patients
with platinum-treated advanced NSCLC, who were unselected for PD-L1 status, were 14% in a separate phase I

cohort of the JAVELIN Solid Tumor trial22 and 15% in the
phase III JAVELIN Lung 200 trial.23 In the current study,
patients with ≥50% and ≥80% PD-L1-positive tumors had
ORRs (by RECIST 1.1) of 22.6% and 26.3%, respectively.
However, a high proportion of patients (28.8%) were
not evaluable for tumor PD-L1 expression, and patient
numbers were low, particularly in the high PD-L1-positive
subgroup (n=38), which hampers interpretation of the
biomarker data. In the overall population, the median
PFS was 4.0 months and the median OS was 14.1 months.
Response rates and PFS assessed using immune-related
criteria were slightly increased compared with analyzes
based on RECIST 1.1. Although the study included small
subgroups with unknown EGFR and ALK mutation status,
ORRs in these patients were similar to the ORR in the
overall population. Safety outcomes were comparable to
previous studies of avelumab and other anti-PD-1/PD-L1
agents in NSCLC.4 12 13 22 24–26
Data from this study can be considered in the context
of similar early-phase studies of other anti-PD-1/PD-L1
antibodies administered as first-
line monotherapy for
PD-L1-positive NSCLC, although cross-trial comparisons
should be interpreted with caution as eligibility criteria
and patient populations may differ, and companion
assays to detect PD-L1 expression were developed independently for each agent. In a cohort of a phase I study
(KEYNOTE-001) in which patients with treatment-naive
NSCLC received pembrolizumab, the ORR was 27%,
median PFS was 6.2 months, and median OS was 22.1
months; efficacy was increased in patients whose tumors
had high PD-L1 expression (≥50% of tumor cells PD-L1+
using the 22C3 assay, which is comparable to ≥80%
of tumor cells PD-
L1+ using the more sensitive 73-10
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Table 4 TRAEs (any grade in ≥5% of patients or grade ≥3
in any patient) and IRRs

Table 5 Immune-related adverse events (any grade in any
patient; n=156)

N=156
Any TRAE, n (%)*
 Fatigue

Patients, n (%)

Any grade

Grade ≥3

107 (68.6)
32 (20.5)

19 (12.2)
4 (2.6)

 Nausea

19 (12.2)

0

 Hypothyroidism

14 (9.0)

0

 Diarrhea

12 (7.7)

0

 Chills

11 (7.1)

0

 Decreased appetite

10 (6.4)

1 (0.6)

 Arthralgia

9 (5.8)

0

 Dry skin

9 (5.8)

0

 Pruritus

8 (5.1)

0

 Fever

8 (5.1)

0

 Vomiting

8 (5.1)

0

 Pneumonitis

5 (3.2)

1 (0.6)

 Lipase increased

4 (2.6)

1 (0.6)

 Hypokalemia

2 (1.3)

1 (0.6)

 Hyponatremia

2 (1.3)

1 (0.6)

 Acute respiratory distress
syndrome

1 (0.6)

1 (0.6)

 Endocrine disorder

1 (0.6)

1 (0.6)

 Hypertension

1 (0.6)

1 (0.6)

 Hypoxia

1 (0.6)

1 (0.6)

 Musculoskeletal chest pain

1 (0.6)

1 (0.6)

 Nephrotic syndrome

1 (0.6)

1 (0.6)

1 (0.6)
40 (25.6)

1 (0.6)
5 (3.2)

 Pneumothorax
IRR, n (%)†

*Incidence of treatment-related IRR based on the single MedDRA
preferred term is not listed.
†Composite term, which includes AEs categorized as IRR, drug
hypersensitivity, or hypersensitivity reaction that occurred on the
day of or day after infusion, in addition to signs and symptoms of
IRR that occurred on the same day of infusion and resolved within
2 days (including AEs classified by investigators as related or
unrelated to treatment).
AE, adverse event; IRR, infusion-related reaction; MedDRA,
Medical Dictionary for Regulatory Activities; TRAE, treatment-
related adverse event.

assay).24 27 In patients with NSCLC treated with first-line
nivolumab in the phase I CheckMate 012 trial, the ORR
was 23%, median PFS was 3.6 months, and median OS was
19.4 months.25 In addition, in patients with PD-L1-high
NSCLC (≥25% PD-L1 expression on tumor cells; SP263
assay) treated with first-
line durvalumab in the phase
I/II 1108 study, the ORR was 27%, median PFS was 5.4
months, and median OS was 21.9 months.26 Subsequent
phase III trials of anti-
PD-1/PD-
L1 antibodies versus
platinum-
based chemotherapy in the first-
line NSCLC
setting have produced conflicting findings. In KEYNOTE024 and KEYNOTE-042, pembrolizumab showed superior
6

Any grade

Grade ≥3

Any immune-related adverse
event
Immune-mediated thyroid
disorder

31 (19.9)

1 (0.6)

15 (9.6)

0

 Hypothyroidism

14 (9.0)

0

 Hyperthyroidism

1 (0.6)

0

Immune-mediated rash or pruritus 12 (7.7)

0

 Pruritus

6 (3.8)

0

 Rash

6 (3.8)

0

 Rash maculopapular

2 (1.3)

0

 Pruritus generalized

1 (0.6)

0

 Rash erythematous

1 (0.6)

0

 Rash macular

1 (0.6)

0

Immune-mediated pneumonitis

5 (3.2)

1 (0.6)

Immune-mediated colitis

3 (1.9)

0

 Diarrhea

2 (1.3)

0

 Colitis

1 (0.6)

0

Immune-mediated adrenal
insufficiency
Autoimmune disorder

1 (0.6)

0

1 (0.6)

0

OS versus platinum-based chemotherapy in patients with
advanced NSCLC with ≥50% and ≥1% PD-
L1 expression on tumor cells, respectively,2 3 which provided the
basis for the approval of pembrolizumab in this setting.
Similarly, in the recently reported IMpower110 trial, first-
line atezolizumab showed superior OS versus platinum-
based chemotherapy in patients with PD-L1-high NSCLC
(PD-
L1 expression on ≥50% of tumor cells and/or
≥10% of tumor-infiltrating immune cells; SP142 assay).28
However, in CheckMate 026, nivolumab did not show
superior OS versus platinum-
based chemotherapy in
patients with PD-L1-positive tumors (≥5% PD-L1 expression on tumor cells; 28-8 assay).4 Similarly, in the MYSTIC
trial, durvalumab alone or in combination with tremelimumab (anticytotoxic T-
lymphocyte-
associated protein
4) was not superior to platinum-based doublet chemotherapy in patients with PD-L1-high NSCLC (≥25% PD-L1
expression on tumor cells; SP263 assay).29 More recently,
several phase III trials have reported superior efficacy for
anti-PD-1 or anti-PD-L1 antibodies combined with chemotherapy versus chemotherapy alone in NSCLC irrespective
of PD-L1 expression.5–7 However, combination regimens
may be associated with increased toxicity burden; thus
checkpoint inhibitor monotherapy with pembrolizumab
remains a standard first-line treatment for PD-L1-high
NSCLC.30 31 The ongoing phase III JAVELIN Lung 100
study (NCT02576574), which was initiated in 2015, is
assessing first-
line avelumab monotherapy compared
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with platinum-based doublet chemotherapy in patients
with PD-L1-positive NSCLC. The primary analysis population in the JAVELIN Lung 100 study consists of patients
with high PD-L1-expressing tumors (≥80% of tumor cells;
73-10 assay); hence, this study will provide an assessment
of avelumab in a patient population similar to those of
earlier trials of anti-PD-1/PD-L1 monotherapy.
In summary, the results from this phase Ib study showed
that avelumab monotherapy has clinical activity and
acceptable safety as a first-line treatment for patients with
advanced NSCLC, providing the rationale for further
studies. Findings from the phase III JAVELIN Lung 100
study will help clarify the potential role of avelumab
monotherapy in the NSCLC treatment landscape.
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